文献速递肾癌与肾肿瘤

1期肾细胞癌手术治疗趋势:基于人群研究的结果

Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study.
PubMed 文献 · BJU Int · 2017-06-09

该研究基于澳大利亚维多利亚州癌症登记处数据,纳入2009、2012和2013年诊断的1836例肾细胞癌患者,分析1期肾细胞癌保留肾单位手术(NSS)的使用变化。结果显示,2009至2013年间NSS使用率增加,T1a期都市地区从43%升至69%,非都市地区从27%升至61%,T1b期从8%升至20%。

要点

  • 2009至2013年澳大利亚1期肾细胞癌的NSS使用率增加。
  • T1a期都市地区NSS比例从2009年43%升至2012年58%和2013年69%。
  • T1a期非都市地区NSS比例从2009年27%升至2012年49%和2013年61%。

核心结论

  • 这项基于人群的研究发现,2009年至2013年间澳大利亚T1期肾肿瘤的NSS使用增加,小肾肿瘤治疗实践日益符合国际指南。

研究设计与样本

  • 基于人群的研究,通过维多利亚州癌症登记处识别2009、2012和2013年诊断的所有成人肾细胞癌病例,由培训的数据提取员查阅医疗记录提取肿瘤和治疗数据,共纳入1836例患者。
  • 采用多变量逻辑回归分析校正潜在混杂因素后NSS使用随时间的变化。

主要发现

  • 1期肿瘤比例2009年为64%、2012年为66%、2013年为69%。
  • T1a期都市地区患者接受NSS比例从2009年43%升至2012年58%(P < 0.05)和2013年69%(P < 0.05)。
  • T1a期非都市地区患者接受NSS比例从2009年27%升至2012年49%和2013年61%(P < 0.01)。
  • 单变量逻辑回归显示,中度合并症(OR 0.57,95%CI 0.35-0.94)或重度合并症(OR 0.58,95%CI 0.33-0.99)、居住非都市地区(OR 0.65,95%CI 0.47-0.90)的患者接受NSS的可能性较低;就诊于高容量医院(≥30例/年:OR 1.79,95%CI 1.21-2.65)和高社会经济地位(OR 1.45,95%CI 1.02-2.07)的患者接受NSS的可能性较高。
  • 多变量分析中,2012年(OR 2.00,95%CI 1.34-2.97)和2013年(OR 3.15,95%CI 2.13-4.68)的T1a期肿瘤患者较2009年更可能接受NSS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether the use of nephron-sparing surgery (NSS) for treatment of stage 1 renal cell carcinoma (RCC) changed between 2009 and the end of 2013 in Australia. PATIENTS AND METHODS: All adult cases of RCC diagnosed in 2009, 2012 and 2013 were identified through the population-based Victorian Cancer Registry. For each identified patient, trained data-abstractors attended treating hospitals or clinician rooms to extract tumour and treatment data through medical record review. Multivariable logistic regression analyses were carried out to examine the significance of change in use of NSS over time, after adjusting for potential confounders. RESULTS: A total of 1 836 patients with RCC were identified. Of these, the proportion of cases with stage 1 tumours was 64% in 2009, 66% in 2012 and 69% in 2013. For T1a tumours, the proportion of patients residing in metropolitan areas receiving NSS increased from 43% in 2009 to 58% in 2012 (P < 0.05), and 69% in 2013 (P < 0.05). For patients residing in non-metropolitan areas, the proportion receiving NSS increased from 27% in 2009 to 49% in 2012, and 61% in 2013 (P < 0.01). Univariable logistic regression showed patients with moderate (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.35-0.94) or severe comorbidities (OR 0.58, 95% CI 0.33-0.99), residing in non-metropolitan areas (OR 0.65, 95% CI 0.47-0.90), were less likely to be treated by NSS, while those attending high-volume hospitals (≥30 cases/year: OR 1.79, 95% CI 1.21-2.65) and those with higher socio-economic status (OR 1.45, 95% CI 1.02-2.07) were more likely to be treated by NSS. In multivariable analyses, patients with T1a tumours in 2012 (OR 2.00, 95% CI 1.34-2.97) and 2013 (OR 3.15, 95% CI 2.13-4.68) were more likely to be treated by NSS than those in 2009. For T1b tumours, use of NSS increased from 8% in 2009 to 20% in 2013 (P < 0.05). CONCLUSION: This population-based study of the management of T1 renal tumours in Australia found that the use of NSS increased over the period 2009 to 2013. Between 2009 and 2013 clinical practice for the treatment of small renal tumours in Australia has increasingly conformed to international guidelines.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. White V, Marco DJT, Bolton D, et al. Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population-based study. BJU Int. 2017. PMID: 28452170. doi:10.1111/bju.13889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。